Braveheart Bio, Inc. (BRVE) Stock Forecast
BRVE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $45.25 average of analyst targets
- Upside to target
- +141.8% from the latest close
- Next earnings
- December 8, 2026 EPS estimate $-0.91
- 52-week range
- $18.58 – $30.00
BRVE analyst ratings
5 analystsNumber of analysts at each rating.
BRVE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BRVE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.44 | −$0.91 | −$0.21 | — | — | 5 |
| Current fiscal year (2026) | −$1.47 | −$2.94 | −$0.65 | −$17.21 | +91.5% | 5 |
| Next fiscal year (2027) | −$1.62 | −$2.34 | −$1.10 | −$1.47 | −10.3% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BRVE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
BRVE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BRVE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$0.33 | −$0.44 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$0.76 | −$1.47 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | −$1.36 | −$1.62 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BRVE earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; BRVE beat in 0 of 1.
What analysts expect from BRVE
5 analysts cover Braveheart Bio; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $45.25, 141.8% above the latest close of $18.71. Analysts expect earnings of −$1.47 per share for 2026, +91.5% from a year earlier. For 2027 the average estimate is −$1.62 per share. Braveheart Bio beat the EPS estimate in 0 of the last 1 quarters.
Related: BRVE income statement, BRVE chart. See the BRVE stock overview for the latest quote and news.
BRVE forecast FAQ
What is Braveheart Bio's price target?
The average analyst price target for Braveheart Bio is $45.25, 141.8% above the latest close of $18.71.
Is Braveheart Bio a buy, hold or sell?
Of 5 analysts covering Braveheart Bio, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Braveheart Bio's EPS forecast?
Analysts forecast −$1.47 per share for 2026 (range −$2.94 to −$0.65); for 2027 the estimate is −$1.62.
When does Braveheart Bio report earnings?
Braveheart Bio is expected to report results for the quarter ending September 30, 2026 on December 8, 2026; the EPS estimate is $-0.91.
Does Braveheart Bio usually beat earnings estimates?
Braveheart Bio reported EPS at or above the analyst estimate in 0 of the last 1 quarters.